{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:14:55Z","timestamp":1789758895141,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873068"],"award-info":[{"award-number":["81873068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274177"],"award-info":[{"award-number":["82274177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174042"],"award-info":[{"award-number":["82174042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["CI2024E003"],"award-info":[{"award-number":["CI2024E003"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["CI2021A03806"],"award-info":[{"award-number":["CI2021A03806"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xcrm.2025.102430","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:19Z","timestamp":1762319659000},"page":"102430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis bone destruction"],"prefix":"10.1016","volume":"6","author":[{"given":"Xiaohui","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-3368","authenticated-orcid":false,"given":"Xiangying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102430_bib1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2025.102430_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.xcrm.2025.102430_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/ar3380","article-title":"Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis","volume":"13","author":"Braun","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102430_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2025.102430_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102430_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3830212","article-title":"Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis","volume":"2020","author":"Fang","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.xcrm.2025.102430_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/biom11010048","article-title":"Rheumatoid Arthritis in the View of Osteoimmunology","volume":"11","author":"Aur\u00e9al","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.xcrm.2025.102430_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116468","article-title":"Rheumatoid arthritis and osteoimmunology: The adverse impact of a deregulated immune system on bone metabolism","volume":"162","author":"Andreev","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.xcrm.2025.102430_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102430_bib11","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102430_bib12","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-Specific CAR T Cells Target Ovarian Cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101270118","article-title":"Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis","volume":"118","author":"Nishio","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102430_bib15","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1182\/bloodadvances.2021004424","article-title":"Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia","volume":"5","author":"Kaeding","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102430_bib16","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: what have we learned in the last decade","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.xcrm.2025.102430_bib17","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI88845","article-title":"Mesothelin\/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102430_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ebiom.2017.08.024","article-title":"Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis","volume":"23","author":"Liu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102430_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.xcrm.2025.102430_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-015-0713-3","article-title":"Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study","volume":"17","author":"Moura","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102430_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2025.102430_bib25","first-page":"355","article-title":"Rheumatoid Arthritis: Early Diagnosis and Treatment","volume":"105","author":"Cush","year":"2021","journal-title":"Med. Clin."},{"key":"10.1016\/j.xcrm.2025.102430_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2017.05.010","article-title":"Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives","volume":"189","author":"Nakken","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.xcrm.2025.102430_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10408363.2020.1775545","article-title":"Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis","volume":"58","author":"Savvateeva","year":"2021","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.xcrm.2025.102430_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3389\/fimmu.2019.00679","article-title":"Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases","volume":"10","author":"Coury","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102430_bib29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10753-023-01914-2","article-title":"HSP90 Exacerbates Bone Destruction in Rheumatoid Arthritis by Activating TRAF6\/NFATc1 Signaling","volume":"47","author":"Wang","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.xcrm.2025.102430_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102430_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"Chang","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.xcrm.2025.102430_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xcrm.2025.102430_bib33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activatorof transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anti-Cancer Agent. Me."},{"key":"10.1016\/j.xcrm.2025.102430_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102430_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.xcrm.2025.102430_bib37","article-title":"Inhibition of mesothelin as a novel strategy for targeting cancer cells","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102430_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120647","article-title":"Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand","volume":"602","author":"Li","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.xcrm.2025.102430_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102430_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105804","article-title":"Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms","volume":"172","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:21:09Z","timestamp":1778919669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2666379125005038"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102430","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis bone destruction","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102430"}}